Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue Health Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Intresional tranexamic acid: 4mg per millilitre injection tranexamic acid injected intralesionaly once in two weeks for 5 weeks
Control Intervention1: Group B:20 patients 50% Glycolic a
Sponsors
Madeshwari M
Eligibility
Inclusion criteria
Inclusion criteria: Patients willing to participate in the study
Exclusion criteria
Exclusion criteria: Before starting the study Pregnant & lactating mothers Patients on oral contraceptive pills, hormonal replacement therapy Active infection /inflammationPhotosensitivity disorders (SLE, porphyria) History of bleeding disorder /Anticoagulant treatment History of allergy Any other mode of treatment for melasma prior to the study During the Study: Develops side effects during the treatment patient wants to discontinue the treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the resolution of hyperpigmentationTimepoint: Baseline,week 4, week 8, week 12 and week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess modified MASI scoreTimepoint: Baseline, week 12 and week 24 | — |
Countries
India
Contacts
Public ContactMADESHWARI M
Chengalpattu medical college and hospital
Outcome results
None listed